At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 767 enrolled
Drug / intervention
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.
In Brief
A Phase 4 clinical trial evaluating Fluad_MF59-adjuvanted trivalent influenza subunit vaccine and Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine for Influenza. Completed, enrolled 767 participants across 23 sites.
Detailed Summary
This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedOct 2010
Primary CompletionOct 2014
TodayJul 2026
First PostedOct 18, 2010
Enrollment StartOct 1, 2010
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.7 years ago
Interventions
Fluad_MF59-adjuvanted trivalent influenza subunit vaccinebiological
Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccinebiological